PROMETHEUS BIOSCIENCES, INC. Operating Income
PROMETHEUS BIOSCIENCES, INC. reported Operating Income of -$48.70 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2023-05-09
- PROMETHEUS BIOSCIENCES, INC. operating income (loss) for the quarter ending 2023-03-31 was -$48.70M.
- PROMETHEUS BIOSCIENCES, INC. operating income (loss) for the quarter ending 2022-12-31 was -$41.33M.
- PROMETHEUS BIOSCIENCES, INC. operating income (loss) for the quarter ending 2022-09-30 was -$38.38M.
- PROMETHEUS BIOSCIENCES, INC. operating income (loss) for the quarter ending 2022-06-30 was -$33.97M.
- PROMETHEUS BIOSCIENCES, INC. operating income (loss) for fiscal 2022 was -$145.78M.
- PROMETHEUS BIOSCIENCES, INC. operating income (loss) for fiscal 2021 was -$87.80M.
- PROMETHEUS BIOSCIENCES, INC. operating income (loss) for fiscal 2020 was -$29.01M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$48.70M 10-Q · filed 2023-05-09 | -$90.03M derived: sum of 2 quarters · filed 2023-05-09 | -$128.42M derived: sum of 3 quarters · filed 2023-05-09 | -$162.38M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | -$41.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$79.71M derived: sum of 2 quarters · filed 2023-02-28 | -$113.68M derived: sum of 3 quarters · filed 2023-02-28 | -$145.78M 10-K · filed 2023-02-28 |
| 2022-09-30 | -$38.38M 10-Q · filed 2022-11-09 | -$72.35M derived: sum of 2 quarters · filed 2022-11-09 | -$104.45M 10-Q · filed 2022-11-09 | -$134.39M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | -$33.97M 10-Q · filed 2022-08-11 | -$66.06M 10-Q · filed 2022-08-11 | -$96.01M derived: sum of 3 quarters · filed 2023-05-09 | -$122.80M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | -$32.10M 10-Q · filed 2023-05-09 | -$62.04M derived: sum of 2 quarters · filed 2023-05-09 | -$88.83M derived: sum of 3 quarters · filed 2023-05-09 | -$107.68M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$29.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$56.74M derived: sum of 2 quarters · filed 2023-02-28 | -$75.58M derived: sum of 3 quarters · filed 2023-02-28 | -$87.80M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$26.79M 10-Q · filed 2022-11-09 | -$45.64M derived: sum of 2 quarters · filed 2022-11-09 | -$57.86M 10-Q · filed 2022-11-09 | -$66.42M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$18.85M 10-Q · filed 2022-08-11 | -$31.07M 10-Q · filed 2022-08-11 | -$39.63M derived: sum of 3 quarters · filed 2023-02-28 | -$47.09M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$12.22M 10-Q · filed 2022-05-12 | -$20.78M derived: sum of 2 quarters · filed 2023-02-28 | -$28.25M derived: sum of 3 quarters · filed 2023-02-28 | -$34.80M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$8.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$16.03M derived: sum of 2 quarters · filed 2023-02-28 | -$22.58M derived: sum of 3 quarters · filed 2023-02-28 | -$29.01M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$7.47M 10-Q · filed 2021-11-12 | -$14.02M derived: sum of 2 quarters · filed 2021-11-12 | -$20.44M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$6.55M 10-Q · filed 2021-08-11 | -$12.98M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$6.42M 10-Q · filed 2021-05-13 |